๐ฌ๐ผ๐๐ฟ ๐ฃ๐ฟ๐ผ๐ฑ๐๐ฐ๐โ๐ ๐ฉ๐ฎ๐น๐๐ฒ ๐๐๐ปโ๐ ๐ฆ๐๐ฎ๐๐ถ๐ฐ. ๐ฆ๐ผ ๐ช๐ต๐ ๐๐ ๐ฌ๐ผ๐๐ฟ ๐ฃ๐ฟ๐ถ๐ฐ๐ถ๐ป๐ด ๐ฆ๐๐ฟ๐ฎ๐๐ฒ๐ด๐?
Imagine your Commercial and Medical teams are preparing for launch. Youโve got an asset with differentiated clinical valueโbut the price is still up for debate.
The Commercial team needs to justify a premium over a competitor.
The Medical team wants to validate value based on real-world access drivers.
Hereโs where Elasticityโข steps in.
Built into eMAX Health Systems’ MAVA platform, ๐๐น๐ฎ๐๐๐ถ๐ฐ๐ถ๐๐โข ๐น๐ฒ๐๐ ๐ฏ๐ผ๐๐ต ๐๐ฒ๐ฎ๐บ๐ ๐๐ฒ๐๐ ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐ ๐๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ๐ ๐๐ถ๐ฑ๐ฒ-๐ฏ๐-๐๐ถ๐ฑ๐ฒ, ๐ฎ๐ป๐ฑ ๐๐ต๐ฒ๐ป ๐บ๐ผ๐ฑ๐ฒ๐น ๐๐ฎ๐น๐๐ฒ ๐ฎ๐ป๐ฑ ๐ฝ๐ฟ๐ถ๐ฐ๐ฒ ๐ถ๐ป ๐ฟ๐ฒ๐ฎ๐น ๐๐ถ๐บ๐ฒ.
- Commercial teams can simulate discounting thresholds using validated product analogs.
- Medical teams can quantify value drivers and build a value index based on payer-tested criteria.
- Together, they can align on what the market will bear and offer clarity before the stakes get high.
Elasticityโข is especially impactful in areas where access complexity meets pricing pressure:
- Oncology โ crowded pipelines, high-cost therapies, complex value frameworks
- Rare Disease โ limited comparators, extreme price sensitivity, payer skepticism
- Cell & Gene Therapy โ launch pricing and value-based contracting are hot-button issues
- Immunology & Rheumatology โ highly competitive categories with tough access barriers
No more siloed spreadsheets. No more guesswork. Just a shared interface thatโs ready when you are.
Itโs how leading pharma teams move from opinion to precision. Let us show you how Elasticityโข makes it possible.